Compliance with buprenorphine medication-assisted treatment and relapse to opioid use

American Journal on Addictions

Volumn 21, Issue 1, 2012, Pages 55-62

  Tkacz, Joseph ^a   Severt, Jamie ^a,b   Cacciola, John ^c   Ruetsch, Charles ^a  

^a Health Analytics LLC   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; BUPRENORPHINE;

ABSTINENCE; ADULT; ALCOHOL ABSTINENCE; ALCOHOLISM; ARTICLE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG DEPENDENCE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OPIATE ADDICTION; PATIENT COMPLIANCE; RELAPSE; SCORING SYSTEM; SEMI STRUCTURED INTERVIEW;

ADULT; ANALGESICS, OPIOID; BUPRENORPHINE; FEMALE; HUMANS; INTERVIEW, PSYCHOLOGICAL; MALE; MIDDLE AGED; MODELS, STATISTICAL; NARCOTIC ANTAGONISTS; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PATIENT COMPLIANCE; QUESTIONNAIRES; RECURRENCE; SEVERITY OF ILLNESS INDEX; SOCIOECONOMIC FACTORS; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 84855360221     PISSN: 10550496     EISSN: 15210391     Source Type: Journal    
DOI: 10.1111/j.1521-0391.2011.00186.x     Document Type: Article

References (54)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Text Revised. Washington, DC: American Psychiatric Association; 2000.
2. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. The NSDUH Report: Trends in Nonmedical Use of Prescription Pain Relievers: 2002 to 2007. Rockville, MD; 2009.
3. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Results from the 2007 National Survey on Drug Use and Health: National Findings (NSDUH Series H-34, DHHS Publication No. SMA 08-4343). Rockville, MD; 2008.
4. Treating opiate addiction, Part I. Detoxification and maintenance. Harv Ment Health Lett. 2004; 21: 4-6.
5. O'Brien CP,. A range of research-based pharmacotherapies for addiction. Science. 1997; 278: 66-70. (Pubitemid 27446273)
6. O'Brien CP, Childress AR, Ehrman R, et al,. Conditioning factors in drug abuse: Can they explain compulsion? J Psychopharmacol. 1998; 12: 15-22. (Pubitemid 28142995)
7. Self DW, Nestler EJ,. Relapse to drug-seeking: Neural and molecular mechanisms. Drug Alcohol Depend. 1998; 51: 49-60. (Pubitemid 28353755)
8. Shaham Y, Highfield D, Delfs J, et al,. Clonidine blocks stress-induced reinstatement of heroin seeking in rats: An effect independent of locus coeruleus noradrenergic neurons. Eur J Neurosci. 2000; 12: 292-302. (Pubitemid 30068434)
9. Stewart J,. Pathways to relapse: The neurobiology of drug- and stress-induced relapse to drug-taking. J Psychiatry Neurosci. 2000; 25: 125-136. (Pubitemid 30233550)
10. Vanderschuren LJ, Everitt BJ,. Drug seeking becomes compulsive after prolonged cocaine self-administration. Science. 2004; 305: 1017-1019. (Pubitemid 39071779)
11. Mattoo SK, Chakrabarti S, Anjaiah M,. Psychosocial factors associated with relapse in men with alcohol or opioid dependence. Indian J Med Res. 2009; 130: 702-708.
12. Chick J, Anton R, Checinski K, et al,. A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol Alcohol. 2000; 35: 587-593.
13. Volpicelli JR, Rhines KC, Rhines JS, et al,. Naltrexone and alcohol dependence. Role of subject compliance. Arch Gen Psychiatry. 1997; 54: 737-742. (Pubitemid 27344101)
14. Schmitz JM, Stotts AL, Rhoades HM, et al,. Naltrexone and relapse prevention treatment for cocaine-dependent patients. Addict Behav. 2001; 26: 167-180. (Pubitemid 32186424)
15. Carroll KM, Fenton LR, Ball SA, et al,. Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: A randomized placebo-controlled trial. Arch Gen Psychiatry. 2004; 61: 264-272. (Pubitemid 38295828)
16. Darke S, Topp L, Ross J,. The injection of methadone and benzodiazepines among Sydney injecting drug users 1996-2000: 5-year monitoring of trends from the Illicit Drug Reporting System. Drug Alcohol Rev. 2002; 21: 27-32.
17. Dole VP, Nyswander ME,. Methadone maintenance treatment. A ten-year perspective. JAMA. 1976; 235: 2117-2119.
18. Joseph H, Stancliff S, Langrod J,. Methadone maintenance treatment (MMT): A review of historical and clinical issues. Mt Sinai J Med. 2000; 67: 347-364.
19. Johnson RE, McCagh JC,. Buprenorphine and naloxone for heroin dependence. Curr Psychiatry Rep. 2000; 2: 519-526.
20. Connock M, Juarez-Garcia A, Jowett S, et al,. Methadone and buprenorphine for the management of opioid dependence: A systematic review and economic evaluation. Health Technol Assess. 2007; 11: 1-171, iii-iv.
21. Maremmani I, Pani PP, Pacini M, et al,. Substance use and quality of life over 12 months among buprenorphine maintenance-treated and methadone maintenance-treated heroin-addicted patients. J Subst Abuse Treat. 2007; 33: 91-98. (Pubitemid 350198612)
22. Soyka M, Zingg C, Koller G, et al,. Retention rate and substance use in methadone and buprenorphine maintenance therapy and predictors of outcome: Results from a randomized study. Int J Neuropsychopharmacol. 2008; 11: 641-653. (Pubitemid 351931822)
23. Magura S, Lee JD, Hershberger J, et al,. Buprenorphine and methadone maintenance in jail and post-release: A randomized clinical trial. Drug Alcohol Depend. 2009; 99: 222-230.
24. Fudala PJ, Bridge TP, Herbert S, et al,. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003; 349: 949-958. (Pubitemid 37064768)
25. Kakko J, Gronbladh L, Svanborg KD, et al,. A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: A randomized controlled trial. Am J Psychiatry. 2007; 164: 797-803. (Pubitemid 46808535)
26. Schottenfeld RS, Chawarski MC, Mazlan M,. Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: A randomised, double-blind, placebo-controlled trial. Lancet. 2008; 371: 2192-2200. (Pubitemid 351885040)
27. Ruetsch C, Cacciola J, Tkacz J,. A national study of a telephonic support service for patients receiving office-based buprenorphine medication asstisted treatment: Study feasibility and sample description. J Subst Abuse Treat. 2010; 39: 307-317.
28. Netherland J, Botsko M, Egan JE, et al,. Factors affecting willingness to provide buprenorphine treatment. J Subst Abuse Treat. 2009; 36: 244-251.
29. McLellan AT, Cacciola JC, Alterman AI, et al,. The Addiction Severity Index at 25: Origins, contributions and transitions. Am J Addict. 2006; 15: 113-124.
30. McLellan AT, Kushner H, Metzger D, et al,. The fifth edition of the Addiction Severity Index. J Subst Abuse Treat. 1992; 9: 199-213.
31. Zanis DA, McLellan AT, Cnaan RA, et al,. Reliability and validity of the Addiction Severity Index with a homeless sample. J Subst Abuse Treat. 1994; 11: 541-548.
32. Zanis DA, McLellan AT, Corse S,. Is the Addiction Severity Index a reliable and valid assessment instrument among clients with severe and persistent mental illness and substance abuse disorders? Community Ment Health J. 1997; 33: 213-227.
33. Brodey BB, Rosen CS, Brodey IS, et al,. Validation of the Addiction Severity Index (ASI) for internet and automated telephone self-report administration. J Subst Abuse Treat. 2004; 26: 253-259. (Pubitemid 38759141)
34. Satre DD, Mertens JR, Arean PA, et al,. Five-year alcohol and drug treatment outcomes of older adults versus middle-aged and younger adults in a managed care program. Addiction. 2004; 99: 1286-1297. (Pubitemid 39330933)
35. Cramer J, Rosenheck R, Kirk G, et al,. Medication compliance feedback and monitoring in a clinical trial: Predictors and outcomes. Value Health. 2003; 6: 566-573. (Pubitemid 37187719)
36. Hollingshead A,. Four Factor Index of Social Status. New Haven, CT: University Press; 1975.
37. DiMatteo MR, Giordani PJ, Lepper HS, et al,. Patient adherence and medical treatment outcomes: A meta-analysis. Med Care. 2002; 40: 794-811.
38. McDermott MM, Schmitt B, Wallner E,. Impact of medication nonadherence on coronary heart disease outcomes. A critical review. Arch Intern Med. 1997; 157: 1921-1929. (Pubitemid 27398356)
39. Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 04-3939. Rockiville, MD: Substance Abuse and Mental Health Services Administration; 2004.
40. Winstock AR, Lea T,. Diversion and injection of methadone and buprenorphine among clients in public opioid treatment clinics in New South Wales, Australia. Subst Use Misuse. 2010; 45: 240-252.
41. RegenceRx-Pharmacy Benefit Management. 2010;. Accessed August 10, 2010.
42. Buprenorphine: An alternative to methadone. Med Lett Drugs Ther. 2003; 45: 13-15.
43. Barnett PG,. Comparison of costs and utilization among buprenorphine and methadone patients. Addiction. 2009; 104: 982-992.
44. Harris AH, Gospodarevskaya E, Ritter AJ,. A randomised trial of the cost effectiveness of buprenorphine as an alternative to methadone maintenance treatment for heroin dependence in a primary care setting. Pharmacoeconomics. 2005; 23: 77-91. (Pubitemid 40194011)
45. ® tablets (buprenorphine hydrochloride and naloxone hydrochloride) [drug label]; 2002. Accessed November 10, 2011.
46. Brewer DD, Catalano RF, Haggerty K, et al,. A meta-analysis of predictors of continued drug use during and after treatment for opiate addiction. Addiction. 1998; 93: 73-92. (Pubitemid 28045140)
47. McMahon RC,. Personality, stress, and social support in cocaine relapse prediction. J Subst Abuse Treat. 2001; 21: 77-87. (Pubitemid 32830154)
48. Simon SL, Dacey J, Glynn S, et al,. The effect of relapse on cognition in abstinent methamphetamine abusers. J Subst Abuse Treat. 2004; 27: 59-66. (Pubitemid 38829780)
49. Walitzer KS, Dearing RL,. Gender differences in alcohol and substance use relapse. Clin Psychol Rev. 2006; 26: 128-148. (Pubitemid 43238384)
50. Simpson D,. Final comments. In:, Simpson D, Sells SB, eds. Opioid Addiction and Treatment: A 12-Year Follow-Up. Malabar, FL: Robert E. Krieger Publishing Co.; 1990.
51. Improving outcomes for opioid-addicted youth. Harv Ment Health Lett. 2009; 25: 7.
52. Eisen A, Kushner H, McLeod M, et al,. An integrated approach to addressing addiction and depression in college students. J Am Coll Health. 2009; 57: 455-456.
53. Del Boca FK, Noll JA,. Truth or consequences: The validity of self-report data in health services research on addictions. Addiction. 2000; 95 (Suppl 3): S347-S360.
54. Darke S,. Self-report among injecting drug users: A review. Drug Alcohol Depend. 1998; 51: 253-263; discussion 267-258.